SMS Pharmaceuticals Limited (NSE:SMSPHARMA) informed stock exchanges on 27th August 2026 that its Board of Directors, acting through circulation, approved a revised date for the company's 38th Annual General Meeting, shifting it from 23rd September 2026 to 29th September 2026, with a corresponding update to the dividend record date and book closure period.
Key Highlights
- The 38th AGM of SMS Pharmaceuticals for FY2025-26 has been rescheduled to Tuesday, 29th September 2026, from the originally announced Wednesday, 23rd September 2026.
- The revised dividend record date is Tuesday, 22nd September 2026, replacing the earlier record date of 16th September 2026, for determining shareholder eligibility to receive the FY26 dividend if approved at the AGM.
- The Register of Members and Share Transfer Books will remain closed from 23rd September 2026 to 29th September 2026, both days inclusive, for the purpose of the 38th AGM.
- The AGM will be conducted via Video Conferencing or Other Audio-Visual Means in accordance with applicable MCA and SEBI circulars, with all other terms from the 31st July 2026 intimation remaining unchanged.
About the Company
SMS Pharmaceuticals Limited (NSE:SMSPHARMA), headquartered in Hyderabad, Telangana, is an active pharmaceutical ingredient (API) manufacturer supplying bulk drug substances to domestic and international markets. The company operates manufacturing facilities in Telangana and serves regulated as well as semi-regulated markets across multiple geographies. Listed on NSE and BSE under the pharma and healthcare sector, it has been engaged in API production and contract manufacturing services for several decades, with the 38th AGM corresponding to its long operational history.
Announcement in Detail
In an exchange filing dated 27th August 2026, SMS Pharmaceuticals Limited stated that its Board of Directors approved, through circulation, a change in the date of the 38th AGM due to unavoidable administrative and scheduling constraints. The meeting, which relates to the financial year ended 31st March 2026, will now be held on Tuesday, 29th September 2026, via Video Conferencing or Other Audio-Visual Means.
As a consequence of the AGM date change, the company revised two related dates. The book closure period was updated to run from Wednesday, 23rd September 2026, to Tuesday, 29th September 2026, both days inclusive. The record date for determining members eligible to receive the dividend for FY2025-26, subject to approval at the AGM, was revised from 16th September 2026 to Tuesday, 22nd September 2026. The company noted that dividend payment will occur within the stipulated time period once approved.
Impact on Investors
Investors will note that the dividend for FY2025-26 has not yet been approved; the AGM on 29th September 2026 is the forum at which shareholders will vote on the distribution. The filing shows that the record date for dividend eligibility has moved to 22nd September 2026, meaning shareholders must hold shares in their account as of that date to qualify, provided the dividend resolution is passed at the meeting.
The disclosed terms indicate that the book closure now runs from 23rd September to 29th September 2026, during which share transfers will not be processed for the purpose of the AGM. Shareholders wishing to participate in the virtual meeting or vote on resolutions should consult the formal AGM notice and related instructions, which the company indicated remain governed by the earlier 31st July 2026 intimation for all other items.
Sector / Market Context
India's pharmaceutical sector, particularly the API segment, has seen continued regulatory focus from both domestic and international agencies. According to SEBI data, virtual AGMs conducted via VC or OAVM have become standard practice for listed companies following MCA circulars introduced during the pandemic period, with the framework remaining available for companies choosing remote-format annual meetings. API manufacturers like SMS Pharmaceuticals operate in a compliance-intensive environment where timely statutory disclosures, including AGM scheduling, form part of broader governance expectations for listed entities.